Ocugen OCGN is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single genetic defect, the platform is intended to work across many underlying ...

Please provide your email address to receive an email when new articles are posted on . Glaucoma is the second leading cause of blindness in the U.S. A primary screening tool for glaucoma is ...

In a recent study published in the journal Mental Health Research, researchers investigated the young adult mental health outcomes of using a GPT3-enabled chatbot. Their analyses of more than 1,000 ...

American companies are increasingly offering psychedelic therapy as a workplace benefit for employees seeking alternative treatments to conditions such as post-traumatic stress disorder, anxiety and ...